NovoCure Limited

NASDAQ:NVCR

Medical - Instruments & Supplies

Healthcare
$10.73 -19.66%

-$3.51 today

Market cap
$1.25B
Beta
0.92
P/E (TTM)
-9.5
EPS (TTM)
-$1.52
52W Low $9.82High $18.92

Volume 1.41M

Average 1.52M

NVCR Debt Repayment

Cash used to repay borrowings during the period.

NovoCure LimitedNASDAQ: NVCR

Debt Repayment · Q1 FY2026 · quarter ended Mar 2026

Debt repayment outflow grows to $0

Q1 FY2026 debt repayment was $0, compared with $0 a year earlier. Trailing-twelve-month debt repayment was -$460.97M. Over 3 fiscal years it compounded at +2443.9% a year.

Context

  • Debt repayment amounted to 70.3% of revenue in FY2025, up 56.5 pp from a year earlier.
  • Debt repayment increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly debt repayment holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$115.24M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0+100.0% QoQ
Last fiscal yearDec 2025
-$460.97M-648.7% YoY
LTMMar 2026
-$460.97M— YoY
Debt Repayment past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-648.7%——
3-year CAGR+2443.9%——
5-year CAGR——
10-year CAGR——

Debt Repayment history

USD · from the cash flow

Latest · FY2025
(460.97M) USD
Year-over-year change
-648.7%

Debt Repayment vs competitors

How NVCR compares with its peers on the latest reported figures

  • NVCR's LTM Mar 2026 debt repayment of $460.97M is the largest of the 4 companies compared; the peer median is $0.
  • Debt repayment amounts to 68.4% of revenue for NVCR, versus a peer median of 0.0%.
NVCR Competitors Peer median
Debt Repayment for NVCR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVCRNovoCure LimitedLTM Mar 2026$460.97M —+2443.9%68.4%
NPCENeuroPace, Inc.LTM Mar 2026$133K ——0.1%
PLSEPulse Biosciences, Inc.LTM Jun 2026$0 ——0.0%
DCTHDelcath Systems, Inc.LTM Mar 2026$0 +100.0%—0.0%
Peer median (excluding NVCR) $0+100.0%—0.0%

Competitors are the stored peer set for NVCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(58.35M)(92.53M)(207.04M)(168.63M)(136.23M)
Depreciation & Amortization10.25M10.62M10.97M(14.41M)14.65M
Deferred Income Tax3.88M0000
Stock-Based Compensation94.9M106.96M115.61M160.04M0
Change in Working Capital29.07M11.8M29.56M(4.3M)(15.13M)
Accounts Receivables5.27M2.55M29.41M(26.36M)(38.94M)
Inventory2.48M(4.34M)(8.92M)2.57M(5.67M)
Accounts Payables27.78M14.26M14.87M19.11M18.96M
Other Working Capital(6.46M)(666K)(5.8M)384K10.52M
Other Non-Cash Items3.01M(6.05M)(22.43M)932K87.67M
Operating Cash Flow82.76M30.79M(73.34M)(26.37M)(49.03M)
Capital Expenditures(24.17M)(21.36M)(27.09M)(42.86M)(26.65M)
Acquisitions (Net)120.66M118.6M000
Purchases of Investments(1.08B)(1.3B)(1B)(875.39M)(821.08M)
Sales of Investments958M1.18B1.21B778M1.29B
Other Investing Activities(120.66M)(118.6M)000
Investing Cash Flow(144.83M)(139.96M)184.15M(140.24M)437.28M
Debt Repayment(26K)(28K)(10K)84.01M(460.97M)
Common Stock Issued4.55M5.22M4.42M4.15M9.77M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities21.18M10.3M11.38M2.16M(146K)
Financing Cash Flow25.7M15.49M15.79M90.32M(451.34M)
Effect of Forex Changes(188K)(97K)131K(174K)394K
Net Change in Cash(36.56M)(93.78M)126.73M(76.47M)(62.7M)
Free Cash Flow58.59M9.43M(100.43M)(69.22M)(75.68M)

NovoCure Limited

NASDAQ:NVCR

Intrinsic Alpha fair value

Locked

Current Price

$10.73

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.